Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Johann von Felden, Angelo Pirozzi et al.|Hepatology|2024Cited by 52
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Calogero Cammà, Tiziana Pressiani et al.|JAMA Oncology|2024Cited by 37